Clinical research on kidney cancer

What is kidney cancer?

Kidney (or renal) cancer is cancer of the kidneys. Kidney cancer is the 7th most common cancer in the UK (excluding non melanoma skin cancer) and around 12,500 kidney cancers were diagnosed in the UK in 2014. It is more common in men than women. The type of kidney cancer depends on the type of cell the cancer started in. Renal cell cancer is the most common type of kidney cancer in adults and more than 80% of kidney cancers diagnosed in the UK are this type. There are three main types of renal cell cancer; clear cell (75%), papillary (10%) and chromophobe (5%). Rarer types of renal cell cancer include carcinoma of the collecting ducts and renal medullary carcinoma. Around 7 to 8% of kidney cancers diagnosed in the UK are transitional cell cancers (TCCs) of the renal pelvis which is the central area of the kidney where urine collects before it goes down the ureter to the bladder. Wilms' tumour is a tumour that can affect children and is different from kidney cancer in adults (this will not be discussed on this page).

Treatment depends on the stage and type of kidney cancers. Some small kidney cancers may not need treatment straight away. Surgery is the main treatment for kidney cancer that hasn't spread to another part of the body. Other treatments include cryotherapy (freezing the cancer, radio wave treatment (RFA), radiotherapy and arterial embolisation (blocking the cancer's blood supply). For kidney cancer that has spread, the main treatment for this is biological therapy. The main types of biological therapies are drugs to activate the patient’s immune system against the cancer (immunotherapy using T-cell checkpoint inhibitors) and/or drugs to prevent the kidney cancer from developing and maintaining a blood supply (anti-angiogenic therapy using tyrosine kinase inhibitors). The departments of surgery, radiology and oncology in Cambridge work closely together to offer these state-of-the-art treatments. In addition, we maintain a portfolio of clinical studies to develop even better treatments for the future and to offer patients the opportunity to take part in research programmes.

Survival depends on many different factors. Generally, for people diagnosed with kidney cancer in England and Wales, more than 70% will survive their cancer for 1 year or more, almost 60% will survive their cancer for 5 years or more and about 50% survive their cancer for 10 years or more after diagnosis.

Research on renal cancers and the clinical service offered to patients is increasing, and it is now a major theme for the Cambridge Cancer Centre. The Centre offers a full range of clinical services for patients and, wherever possible, offers opportunities to patients to take part in clinical research. We maintain a highly active clinical trials portfolio, recruiting around a third of patients into clinical trials. The centre runs internationally recognised programmes in the genetics of the disease and the metabolic consequences of those genetic abnormalities, in understanding tumour biology and in the treatment of resulting malignancies.

Clinical trials on renal cancer

Our portfolio of trials is continuously in development. We participate in a range of national and international trials investigating novel therapies for patients at risk of their kidney cancer returning after surgery or whose disease has already spread to other parts of the body.

Current open trials in Cambridge

The table below lists the current open trials for kidney cancer coordinated by the Cambridge Cancer Trials Centre. If you would like further information about how to take part in any of the clinical trials listed here, please talk to your cancer specialist as patients usually need to be referred by their doctor.



University of Cambridge, Cambridge University Hospitals NHS Foundation Trust
Department of Surgery
Cambridge University Hospitals NHS Foundation Trust
Department of Oncology, Cancer Research UK Cambridge Institute
Cambridge University Hospitals NHS Foundation Trust, University of Cambridge
MRC Cancer Unit
Titlesort descending Trial description Contact name Trial end date Trial start date
ARTIST ‘ARTIST’ stands for a translational research Approach to development of optimal Renal cancer Treatments In Surgical and systemic Therapy patients, a single-centre translational research study designed to identify and characterize novel biomarkers for the optimal detection, monitoring and treatment of renal cell cancer (RCC). Dr James Jones 31 Dec 2025 4 Jan 2021
COSMIC-313 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk Dr Kate Fife 1 Mar 2025 6 Dec 2019
MITRE Microbiome Immunotherapy Toxicity and Response Evaluation (MITRE) An observational study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy Dr Pippa Corrie 8 Jul 2025 30 Mar 2021
WIRE ‘WIRE’ stands for WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer, a clinical trial that makes opportunistic investigational use of the existing 4-week surgical window-of-opportunity between the decision to operate on surgically resectable renal cell cancer (RCC) and surgery itself. Professor Grant Stewart 31 Jan 2025 28 Aug 2020